Patient-voice layer — hypertension

Last updated: 2026-09-01

What this layer is

Hypertension's patient experience is unusual among the conditions in this knowledge base: the disease itself produces no symptoms, the treatment often does, and the benefit is statistical and decades away. Almost everything a patient feels about hypertension is about the label, the pills, the measurements and the appointments — not about the disease. This layer collects what patients say about that, in aggregate, from public sources.

It contains four files:

File	Contents
README.md	This file — method, ethics, scope, coverage limits
organizations.md	Directory of organisations worldwide, each verified by retrieving its site, with URL and access date
themes.md	Thematic synthesis of patient-reported experience, each theme supported by ≥2 independent sources
sources.md	Annotated source list with an honest statement of what this layer does and does not cover

The wiki-facing synthesis is wiki/patient-experience-and-advocacy.md.

Method

1. Published qualitative research was located by PubMed E-utilities searches during the build session of 2026-09-01, using title-field restrictions on hypertension/antihypertensive combined with qualitative, adherence, experiences, perceptions, beliefs and self-monitoring, plus targeted searches for qualitative evidence syntheses. Every PubMed identifier used in this layer was resolved by a live query in that session; none was written from memory.
2. Organisations were identified from the guideline and campaign literature and from the professional societies that author it, then verified by retrieving each organisation's website on 2026-09-01. The page title and, where present, the site's own description were recorded. Any organisation whose site did not resolve, or resolved to an unrelated entity, was excluded — one candidate (a national heart foundation in India) was dropped for exactly that reason.
3. Themes were built by reading the qualitative syntheses first and the primary qualitative studies second, then requiring at least two independent sources before a theme was recorded. Where a theme is supported by a single study, it is not listed as a theme; it appears, if at all, as a noted observation in sources.md.
4. Nothing was inferred from clinical trial data about how patients feel. Where a trial's qualitative or process-evaluation component exists (QUARTET, TASMINH4, SNAP-HT, the barbershop trial), that component is cited rather than the trial's clinical result.

Ethics rules observed

These follow CONVENTIONS.md §3 and are binding on this layer:

• Public sources only. Peer-reviewed qualitative research, organisation websites, and published campaign material. No social-media posts, patient-forum threads, private correspondence, or content behind a login.
• Paraphrase rather than quote. Where a quotation is unavoidable it is ≤15 words and attributed to its published source. In practice this layer contains no participant quotations at all: everything is reported at the level of themes identified by the original researchers.
• No names or identifying details of private individuals. No participant names, ages combined with locations, occupations, diagnoses-plus-demographics, or any combination that could identify a person. Public figures and named organisational spokespeople would be permissible; none is used.
• Themes reported in aggregate. Findings are attributed to studies and syntheses, never to individuals. Where a study reports counts, the counts are of participants in the study, not of identifiable people.
• No medical advice. This is a research knowledge base. Nothing here is framed as guidance to a patient.
• Coverage limits stated honestly. See the closing section of sources.md.

Scope note specific to hypertension

Two structural features shape this layer and should be read before anything in it:

1. There is very little patient-founded advocacy in hypertension. Unlike conditions with a distinct illness identity, hypertension's advocacy is carried almost entirely by professional societies (International Society of Hypertension, European Society of Hypertension, Hypertension Canada, Hypertension Australia), general cardiovascular charities (British Heart Foundation, Heart Foundation Australia, Heart and Stroke Foundation of Canada, World Heart Federation) and public-health bodies (WHO, PAHO, national agencies). Blood Pressure UK is the clearest exception. This is a rational response to an asymptomatic condition — but it means the patient voice reaches the literature mainly through research commissioned by clinicians, and the priorities set in this field are professional priorities.
2. The qualitative literature is geographically broad but methodologically narrow. There are good qualitative studies from Sweden, the Netherlands, the UK, the US, Greece, Malaysia, Indonesia, Tanzania, Uganda, Nigeria and India — but they overwhelmingly ask the same question: why don't people take their tablets? Studies asking what patients want from care, or what they think the diagnosis means for their lives, are much rarer.

What would improve this layer

• A validated patient-reported outcome measure specific to hypertension treatment burden. The PubMed search repeated on 2026-09-01 located treatment-satisfaction, adherence and quality-of-life instruments but no generally used hypertension-specific treatment-burden measure; trials therefore usually report pressure and adverse events rather than the costs patients describe.
• Qualitative work with people who have stopped treatment, rather than with clinic attenders.
• Any organised patient-led research agenda in hypertension, against which the professional agenda could be compared.